Non-Small Cell Lung Cancer (NSCLC) is one of the most common type of cancer and also one of the major reasons for cancer-related mortality globally. In 2012, there were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 – a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options.
Browse more detail information about Non-Small Cell Lung Cancer Therapeutics:
Scope of Non-Small Cell Lung Cancer Therapeutics:
The NSCLC pipeline is wide and diverse, with an increased presence of mAbs and targeted therapies.
- What are the main targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet requirements such as less treatment options for squamous cell patients?
- What implications the increased focus on targeted therapies will have on the future of NSCLC treatment?
The NSCLC Asia-Pacific industry will be valued at $4.9 billion in 2022, growing from $2.7 billion in 2015 at a CAGR of 8.7%.
- How will immunotherapies such as Keytruda are going to contribute to the growth?
- What effect will patent expirations of currently branded therapies have on market value?
Various late-stage pipeline therapies with strong clinical record have the potential to enter the market over the forecasted period.
- How have the late-stage therapies performed in clinical trials?
- How would the approval of rociletinib to treat T790M mutant patients affect the competitive landscape, with its competitor osimertinib (AZD-9291) already approved in Japan in 2016?
- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?
The market forecasts show that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
- How will the annual cost of therapy and industry size vary between the five Asia-Pacific markets?
- How could changes in risk factors such as population age, smoking habits and pollution impact the market?
Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?
Get a PDF Sample of Non-Small Cell Lung Cancer Therapeutics:
Reasons to buy Non-Small Cell Lung Cancer Therapeutics:
This report will allow you to:
Understand the current clinical and commercial scenario by considering disease pathogenesis, diagnosis, prognosis, and the treatment options that are available at each stage of diagnosis, including a clinical comparison of marketed therapies.
Visualize the composition of the NSCLC industry in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive gaps understanding in the current scenario.
Analyse the NSCLC pipeline and categorise pipeline therapies on the basis of molecule type, stage of development and molecular target.
Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecasted period, highlighting clinical performance, potential commercial positioning, and how they are going to compete with other therapies.
Predict NSCLC market growth scope in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across China, Australia, India, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.
Have any query? ask our expert @ http://www.absolutereports.com/enquiry/pre-order-enquiry/10186814
List of Figures, Tables and Charts Available in Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 – Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market
1.1 List of Tables
Table 1: NSCLC Therapeutics Market, Tumor Node Metastasis Classification 22
Table 2: NSCLC Therapeutics Market, Eastern Co-operative Oncology Group Criteria 23
Table 3: NSCLC Therapeutics Market, Treatment Options 24
Table 4: NSCLC Therapeutics Market, Global, All Pipeline Products, Discovery, 2015 113
Table 5: NSCLC Therapeutics Market, Global, All Pipeline Products, Preclinical, 2015 114
Table 6: NSCLC Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2015 118
Table 7: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase I, 2015 119
Table 8: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase II, 2015 123
Table 9: NSCLC Therapeutics Market, Global, All Pipeline Products, Phase III, 2015 128
Table 10: NSCLC Therapeutics Market, Global, All Pipeline Products, Pre-registration Phase, 2015 130
Table 11: NSCLC Therapeutics Market, APAC, Market Forecast, 2015-2022 130
Table 12: NSCLC Therapeutics Market, India, Market Forecast, 2015-2022 131
Table 13: NSCLC Therapeutics Market, China, Market Forecast, 2015-2022 131
Table 14: NSCLC Therapeutics Market, Australia, Market Forecast, 2015-2022 131
Table 15: NSCLC Therapeutics Market, South Korea, Market Forecast, 2015-2022 132
Table 16: NSCLC Therapeutics Market, Japan, Market Forecast, 2015-2022 132
Get Discount on Non-Small Cell Lung Cancer Therapeutics:
About Absolute Report:
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in-depth market research. We are one of the top report resellers in the market dedicated towards bringing you an ingenious concoction of data parameters.
Mr. Ameya Pingaley
+1-408 520 9750
Get more market research related news @ www.marketresearch.news